The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
The Human Histone Deacetylase Family
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 5×
“A novel NAD-dependent histone deacetylase activity was recently demonstrated for both yeast and mouse Sir2 [88, 89].”
BackgroundInfluentialActivation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins
Frye, R. A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3000 · Cited by 1,409
Retinoblastoma protein recruits histone deacetylase to repress transcription
Brehm, A., Miska, E. A., McCance, D. J., Reid, J. L., Bannister, A. J., & Kouzarides, T. (1998) · Nature · doi:10.1038/35404 · Cited by 1,230
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
The DNA sequence of human chromosome 22
Dunham, I., Hunt, A. R., Collins, J. E., Bruskiewich, R., Beare, D. M., Clamp, M., Smink, L. J., Ainscough, R., Almeida, J. P., Babbage, A., et al. (1999) · Nature · doi:10.1038/990031 · Cited by 1,157
The Insulin-Like Growth Factor-Binding Protein (IGFBP) Superfamily*
Hwa, V., Oh, Y., & Rosenfeld, R. G. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0382 · Cited by 1,079
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci
Rountree, M. R., Bachman, K. E., & Baylin, S. B. (2000) · Nature Genetics · doi:10.1038/77023 · Cited by 1,052
The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases
Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., Pillus, L., & Sternglanz, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110148297 · Cited by 970
Cited by
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin.
Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.031 · Cited by 916
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence
Langley, E. (2002) · The EMBO Journal · doi:10.1093/emboj/21.10.2383 · Cited by 860
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740
MEF2: a calcium-dependent regulator of cell division, differentiation and death
McKinsey, T. A., Zhang, C. L., & Olson, E. N. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)02031-x · Cited by 687
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan, M., MacGrogan, D., Rodgers, J. T., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602909200 · Cited by 626
Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells
Li, M., van Esch, B. C. A. M., Wagenaar, G. T. M., Garssen, J., Folkerts, G., & Henricks, P. A. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.003 · Cited by 614
The Mammalian SIR2α Protein Has a Role in Embryogenesis and Gametogenesis
McBurney, M. W., Yang, X., Jardine, K., Hixon, M., Boekelheide, K., Webb, J. R., Lansdorp, P. M., & Lemieux, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.38-54.2003 · Cited by 611
(2011) · PubMed Central · Cited by 560
Grozinger, C. M., & Schreiber, S. L. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00092-3 · Cited by 537
Histone deacetylase inhibitors as new cancer drugs
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523
(2003) · PubMed · Cited by 519
The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases
Yang, X.-J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh252 · Cited by 515
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
Histone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
Control of muscle development by dueling HATs and HDACs
McKinsey, T. A., Zhang, C. L., & Olson, E. N. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00224-0 · Cited by 414
Epigenetics and cardiovascular disease
Ordovás, J. M., & Smith, C. E. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.104 · Cited by 402
Bhaskara, S., Chyla, B. J., Amann, J. M., Knutson, S. K., Cortez, D., Sun, Z.-W., & Hiebert, S. W. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.030 · Cited by 372
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S. U., Joo, H. J., & Kim, D. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 346
Histone deacetylase inhibitors
Monneret, C. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.10.001 · Cited by 338
Seigneurin-Berny, D., Verdel, A., Curtet, S., Lemercier, C., Garin, J., Rousseaux, S., & Khochbin, S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.23.8035-8044.2001 · Cited by 335
“Class I HDACs are homologous to yeast RPD3, while class II members are related to yeast HDA1 and class III members are related to yeast SIR2 deacetylase (13, 20).”
BackgroundThe future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter
Westendorf, J. J., Zaidi, S. K., Cascino, J. E., Kahler, R., van Wijnen, A. J., Lian, J. B., Yoshida, M., Stein, G. S., & Li, X. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7982-7992.2002 · Cited by 324
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
Biological roles and mechanistic actions of co-repressor complexes
Jepsen, K., & Rosenfeld, M. G. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.4.689 · Cited by 317
Epigenetics—An Epicenter of Gene Regulation: Histones and Histone‐Modifying Enzymes
Biel, M., Wascholowski, V., & Giannis, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461346 · Cited by 316
Gaughan, L., Logan, I. R., Cook, S., Neal, D. E., & Robson, C. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203423200 · Cited by 310
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
Li, L.-C., Carroll, P. R., & Dahiya, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji010 · Cited by 299
HDAC6 Expression Is Correlated with Better Survival in Breast Cancer
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, M., Hayashi, S.-I., & Iwase, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0455 · Cited by 293
Clinical and Experimental Applications of Sodium Phenylbutyrate
Iannitti, T., & Palmieri, B. (2011) · Drugs in R & D · doi:10.1007/bf03259725 · Cited by 270
Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors
Antos, C. L., McKinsey, T. A., Dreitz, M., Hollingsworth, L. M., Zhang, C.-L., Schreiber, K., Rindt, H., Gorczynski, R. J., & Olson, E. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303113200 · Cited by 269
Li, W., Zhang, B., Tang, J., Cao, Q., Wu, Y., Wu, C., Guo, J., Ling, E.-A., & Liang, F. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4181-06.2007 · Cited by 265
Structural Basis of Inhibition of the Human NAD+-Dependent Deacetylase SIRT5 by Suramin
Schuetz, A., Min, J., Antoshenko, T., Wang, C.-L., Allali-Hassani, A., Dong, A., Loppnau, P., Vedadi, M., Bochkarev, A., Sternglanz, R., et al. (2007) · Structure · doi:10.1016/j.str.2007.02.002 · Cited by 261
Histone deacetylase as a therapeutic target
Krämer, O. H., Göttlicher, M., & Heinzel, T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00438-6 · Cited by 257
HDAC6 as privileged target in drug discovery: A perspective
Pulya, S., Amin, S. A., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105274 · Cited by 253
Histone deacetylase inhibitors: from target to clinical trials
Kelly, W. K., O’Connor, O. A., & Marks, P. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1695 · Cited by 253
Human HDAC7 Histone Deacetylase Activity Is Associated with HDAC3in Vivo
Fischle, W., Dequiedt, F., Fillion, M., Hendzel, M. J., Voelter, W., & Verdin, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104935200 · Cited by 232
SMRT Derepression by the IκB Kinase α
Hoberg, J. E., Yeung, F., & Mayo, M. W. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.010 · Cited by 220
Regulation of histone deacetylase 2 by protein kinase CK2
Tsai, S.-C., & Seto, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204149200 · Cited by 196
Nicotinamide Clearance by Pnc1 Directly Regulates Sir2-Mediated Silencing and Longevity
Gallo, C. M., Smith, D. L., & Smith, J. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.1301-1312.2004 · Cited by 193
Tong, J. J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.5.1114 · Cited by 181
(2002) · PubMed · Cited by 156
Smith, W. L., & Edlind, T. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3532-3539.2002 · Cited by 147
Molecular signature of oncogenic ras-induced senescence
Mason, D. X., Jackson, T. J., & Lin, A. W. (2004) · Oncogene · doi:10.1038/sj.onc.1208172 · Cited by 127
Rombouts, K. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5577 · Cited by 111
Structure of Histone Deacetylases
Marmorstein, R. (2001) · Structure · doi:10.1016/s0969-2126(01)00690-6 · Cited by 97
Chen, Z., Clark, S., Birkeland, M., Sung, C.-M., Lago, A., Liu, R., Kirkpatrick, R., Johanson, K., Winkler, J. D., & Hu, E. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00322-1 · Cited by 87
Histone deacetylases in fungi: novel members, new facts
Trojer, P. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg473 · Cited by 86
Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer
Hsieh, C.-L., Ma, H.-P., Su, C.-M., Chang, Y.-J., Hung, W.-Y., Ho, Y.-S., Huang, W.-J., & Lin, R.-K. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.092 · Cited by 47
Measuring histone deacetylase inhibition in the brain
Reddy, D. S., Wu, X., Golub, V. M., Dashwood, W. M., & Dashwood, R. H. (2018) · Current Protocols in Pharmacology · doi:10.1002/cpph.41 · Cited by 33
Zeremski, M., Stricker, J. R., Fischer, D., Zusman, S. B., & Cohen, D. (2003) · genesis · doi:10.1002/gene.10159 · Cited by 17
Metadata
- Authors
- Gray, S. G., & Ekström, T. J.
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2001-01
- Volume
- 262
- Issue
- 2
- Pages
- 75-83
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W1995902306
- Cited by
- 546
- References
- 102
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.